We are live on ! Find out more
EBAC

European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC

Delisted

EBAC was delisted on the 2nd of March, 2023.

Back to rankings

45 hedge funds and large institutions have $69.6M invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

26% more capital invested

Capital invested by funds: $55.2M → $69.6M (+$14.4M)

10% more funds holding

Funds holding: 41 → 45 (+4)

Holders
45
Holders Change
+4
Holders Change %
+9.76%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
1
Closed
2
Calls
$8K
Puts
–
Net Calls
+$8K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HP
Hartree Partners
New York
+$7.3M
2
PC
Periscope Capital
Ontario, Canada
+$4.52M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.61M
4
AMH
Apollo Management Holdings
New York
+$971K
5
Marshall Wace
Marshall Wace
United Kingdom
+$856K

Top Sellers

Rank Fund Capital Flow
1
AC
Athanor Capital
New York
-$1.43M
2
Millennium Management
Millennium Management
New York
-$87.7K
3
WAM
Wolverine Asset Management
Illinois
-$4K
Name Holding Trade Value Shares
Change 		Change in
Stake
HP
1
Hartree Partners
New York
$7.49M +$7.3M +750,000 New
Citadel Advisors
2
Citadel Advisors
Florida
$6.07M +$1.37K +141 +0%
PC
3
Periscope Capital
Ontario, Canada
$4.91M +$4.52M +464,400 +1,104%
Macquarie Group
4
Macquarie Group
Australia
$4.88M – – –
LA
5
Linden Advisors
New York
$4.83M – – –
Marshall Wace
6
Marshall Wace
United Kingdom
$4.01M +$856K +87,961 +27%
D.E. Shaw & Co
7
D.E. Shaw & Co
New York
$3.82M +$1.61M +165,129 +72%
ACA
8
Arena Capital Advisors
California
$2.92M – – –
SCM
9
Suvretta Capital Management
New York
$2.91M – – –
WP
10
Woodline Partners
California
$2.67M – – –
MI
11
MMCAP International
Cayman Islands
$2.42M – – –
RCM
12
Radcliffe Capital Management
Pennsylvania
$1.94M – – –
SC
13
Sculptor Capital
New York
$1.94M – – –
Alyeska Investment Group
14
Alyeska Investment Group
Illinois
$1.45M – – –
FTCM
15
Fir Tree Capital Management
New York
$1.45M – – –
GCM
16
Ghisallo Capital Management
Massachusetts
$1.21M – – –
PMAM
17
Picton Mahoney Asset Management
Ontario, Canada
$1.21M – – –
MCM
18
Moore Capital Management
New York
$1.21M – – –
Millennium Management
19
Millennium Management
New York
$1.17M -$87.7K -9,013 -7%
AA
20
AQR Arbitrage
Connecticut
$971K – – –
DCM
21
Dupont Capital Management
Delaware
$970K – – –
Hudson Bay Capital Management
22
Hudson Bay Capital Management
Connecticut
$969K – – –
TCM
23
Tenor Capital Management
New York
$969K – – –
AMH
24
Apollo Management Holdings
New York
$967K +$971K +99,791 New
CCM
25
CAAS Capital Management
New York
$937K – – –
1
2

EBAC Hedge Fund Activity: Q4 2021 in Review

45 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q4 2021, worth a combined $69.6M — up 26% from $55.2M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new EBAC positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Hartree Partners, opening a new position worth an estimated $7.3M. The largest seller was Athanor Capital, exiting entirely with an estimated $1.43M sold.

  • 45 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q4 2021, up from 41 in Q3 2021.
  • Funds reported $69.6M of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q4 2021, up 26% quarter-over-quarter.
  • 6 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q4 2021 and 2 closed out, a net change of +4 holders.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares buyer in Q4 2021 was Hartree Partners, an estimated $7.3M added.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q4 2021 was Athanor Capital, an estimated $1.43M sold.

Based on aggregated 13F filings for Q4 2021.